Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT

v3.23.1
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)
Total
Agribody Technologies, Inc.
Entira, Inc
Camelina Company Espana SL
Preferred Stock
Common Stock
Common Stock
Agribody Technologies, Inc.
Common Stock
Entira, Inc
Common Stock
Camelina Company Espana SL
Additional Paid-In Capital
Additional Paid-In Capital
Agribody Technologies, Inc.
Additional Paid-In Capital
Entira, Inc
Additional Paid-In Capital
Camelina Company Espana SL
Accumulated other comprehensive loss
Accumulated Deficit
Treasury Stock
Non - controlling Interests
Beginning Balance at Dec. 31, 2020 $ (28,734,073)                 $ 31,670,954       $ 0 $ (66,232,439) $ 0 $ 5,468,900
Beginning Balance, Shares at Dec. 31, 2020         13 358,499                      
Share-based compensation from issuance of options and compensation-based warrants 691,821                 691,821              
Shares issued to employees 768,368                 766,976              
Shares issued to employees, Shares           1,392                      
Exercise of stock options 12,005                 10,880              
Exercise of stock options, Shares           1,125                      
Shares issued upon reverse split to avoid fractional shares                   (19)              
Shares issued upon reverse split to avoid fractional shares, Shares           19                      
Conversion of note payable to shares 476,036                 460,168              
Conversion of note payable to shares, Shares           15,868                      
Purchase of Business Acquisition   $ 5,000,000 $ 2,463,307 $ 6,712,462             $ 4,991,695 $ 2,459,236 $ 6,698,922        
Purchase of Business Acquisition, Shares             8,305 4,071 13,540                
Conversion of Series B Preferred to Common, Shares         (13) 11,818                      
Conversion of Series B Preferred to Common                   (11,805)              
Conversion of convertible notes, Shares           537                      
Conversion of convertible notes 308,889                 308,352              
Issuance of common stock for cash 3,100,000                 3,095,040              
Issuance of common stock for cash, Shares           4,960                      
Net loss (51,415,508)                           (51,415,508)    
Ending Balance at Dec. 31, 2021 (60,616,693)                 51,142,220       0 (117,647,947) 0 5,468,900
Ending Balance, Shares at Dec. 31, 2021         0 420,134                      
Share-based compensation from issuance of options and compensation-based warrants $ 2,379,641                 2,379,471              
Share-based compensation from issuance of options and compensation-based warrants, Shares 170                                
Exercise of stock options $ 131,803                 128,631              
Exercise of stock options, Shares           3,172                      
Purchase of Business Acquisition, Shares   830,526 407,150 1,353,951                          
Issuance of warrants 84,330,951                 84,330,951              
Issuance of warrants in subsidiary 14,967,120                               14,967,120
Deemed contribution in connection with issuance of preferred stock to Senior Lenders 9,942,069                 9,942,069              
Accretion of 15.00% Series C preferred stock (25,290,758)                 (25,290,758)              
Foreign currency translation adjustment 72,514                         72,514      
Acquisition of common stock at cost (15,935)                             (15,935)  
Net loss (54,108,708)                           (54,108,708)    
Ending Balance at Dec. 31, 2022 $ (28,207,996)                 $ 122,632,584       $ 72,514 $ (171,756,655) $ (15,935) $ 20,436,020
Ending Balance, Shares at Dec. 31, 2022         0 423,476